Jiuwei Cui

机构：Jilin University, First Hospital of Jilin University · ORCID：0000-0001-6496-7550

发表论文 629 篇 · 总被引 16996 次 · h-index 61

代表论文

• Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer (2025 · New England Journal of Medicine · 被引 123)
• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 60)
• Therapeutic advances in sarcopenia management: From traditional interventions to personalized medicine (2025 · Clinical Nutrition · 被引 21)
• Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications (2025 · Frontiers in Immunology · 被引 19)
• Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. (2025 · Journal of Clinical Oncology · 被引 14)
• Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 13)